Emergent BioSolutions (EBS) Revenue & Revenue Breakdown
Emergent BioSolutions Revenue Highlights
Latest Revenue (Y)
$1.05B
Latest Revenue (Q)
$254.70M
Main Segment (Y)
Product
Main Geography (Y)
Services Segment
Emergent BioSolutions Revenue by Period
Emergent BioSolutions Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $1.05B | -6.39% |
| 2022-12-31 | $1.12B | -37.47% |
| 2021-12-31 | $1.79B | 15.26% |
| 2020-12-31 | $1.56B | 40.63% |
| 2019-12-31 | $1.11B | 41.36% |
| 2018-12-31 | $782.40M | 39.50% |
| 2017-12-31 | $560.87M | 14.75% |
| 2016-12-31 | $488.78M | -6.50% |
| 2015-12-31 | $522.79M | 16.14% |
| 2014-12-31 | $450.14M | 43.93% |
| 2013-12-31 | $312.75M | 10.95% |
| 2012-12-31 | $281.89M | 3.11% |
| 2011-12-31 | $273.38M | -4.47% |
| 2010-12-31 | $286.17M | 21.89% |
| 2009-12-31 | $234.79M | 31.49% |
| 2008-12-31 | $178.55M | -2.38% |
| 2007-12-31 | $182.91M | 19.76% |
| 2006-12-31 | $152.73M | 16.87% |
| 2005-12-31 | $130.69M | 56.52% |
| 2004-12-31 | $83.49M | 49.71% |
| 2003-12-31 | $55.77M | -28.99% |
| 2002-12-31 | $78.54M | 73.35% |
| 2001-12-31 | $45.31M | - |
Emergent BioSolutions generated $1.05B in revenue during NA 2023, up -6.39% compared to the previous quarter, and up 134.11% compared to the same period a year ago.
Emergent BioSolutions Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $254.70M | -7.92% |
| 2023-12-31 | $276.60M | 2.26% |
| 2023-09-30 | $270.50M | -19.95% |
| 2023-06-30 | $337.90M | 104.66% |
| 2023-03-31 | $165.10M | -50.08% |
| 2022-12-31 | $330.70M | 37.79% |
| 2022-09-30 | $240.00M | -1.11% |
| 2022-06-30 | $242.70M | -21.07% |
| 2022-03-31 | $307.50M | -57.48% |
| 2021-12-31 | $723.20M | 119.82% |
| 2021-09-30 | $329.00M | -17.23% |
| 2021-06-30 | $397.50M | 15.89% |
| 2021-03-31 | $343.00M | -41.17% |
| 2020-12-31 | $583.00M | 51.35% |
| 2020-09-30 | $385.20M | -2.41% |
| 2020-06-30 | $394.70M | 105.04% |
| 2020-03-31 | $192.50M | -46.59% |
| 2019-12-31 | $360.40M | 15.59% |
| 2019-09-30 | $311.80M | 28.21% |
| 2019-06-30 | $243.20M | 27.60% |
| 2019-03-31 | $190.60M | -29.59% |
| 2018-12-31 | $270.70M | 55.89% |
| 2018-09-30 | $173.65M | -21.14% |
| 2018-06-30 | $220.20M | 86.90% |
| 2018-03-31 | $117.81M | -39.21% |
| 2017-12-31 | $193.81M | 29.70% |
| 2017-09-30 | $149.43M | 48.29% |
| 2017-06-30 | $100.77M | -13.77% |
| 2017-03-31 | $116.86M | -22.95% |
| 2016-12-31 | $151.66M | 6.12% |
| 2016-09-30 | $142.91M | 40.82% |
| 2016-06-30 | $101.49M | -8.57% |
| 2016-03-31 | $111.00M | -33.97% |
| 2015-12-31 | $168.10M | 1.92% |
| 2015-09-30 | $164.94M | 30.79% |
| 2015-06-30 | $126.11M | 98.19% |
| 2015-03-31 | $63.63M | -57.00% |
| 2014-12-31 | $147.97M | 7.26% |
| 2014-09-30 | $137.95M | 25.04% |
| 2014-06-30 | $110.33M | 104.75% |
| 2014-03-31 | $53.88M | -45.08% |
| 2013-12-31 | $98.11M | 10.11% |
| 2013-09-30 | $89.10M | 8.09% |
| 2013-06-30 | $82.44M | 91.27% |
| 2013-03-31 | $43.10M | -54.44% |
| 2012-12-31 | $94.61M | 42.07% |
| 2012-09-30 | $66.59M | -5.38% |
| 2012-06-30 | $70.38M | 39.89% |
| 2012-03-31 | $50.31M | -53.39% |
| 2011-12-31 | $107.95M | 83.70% |
| 2011-09-30 | $58.76M | -33.33% |
| 2011-06-30 | $88.14M | 375.59% |
| 2011-03-31 | $18.53M | -82.05% |
| 2010-12-31 | $103.25M | 39.55% |
| 2010-09-30 | $73.99M | 19.07% |
| 2010-06-30 | $62.14M | 32.77% |
| 2010-03-31 | $46.80M | -13.02% |
| 2009-12-31 | $53.80M | 24.34% |
| 2009-09-30 | $43.27M | -40.88% |
| 2009-06-30 | $73.19M | 13.44% |
| 2009-03-31 | $64.52M | 80.47% |
| 2008-12-31 | $35.75M | -36.84% |
| 2008-09-30 | $56.60M | 30.16% |
| 2008-06-30 | $43.48M | 1.79% |
| 2008-03-31 | $42.72M | -52.34% |
| 2007-12-31 | $89.64M | - |
Emergent BioSolutions generated $254.70M in revenue during Q2 2024, up -7.92% compared to the previous quarter, and up 77.02% compared to the same period a year ago.
Emergent BioSolutions Revenue Breakdown
Emergent BioSolutions Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Product | $944.50M | $966.20M | - | - | - |
| Contracts and Grants | $26.30M | $41.40M | $71.30M | - | - |
| Service | $72.80M | - | - | - | - |
| Commercial Product | $497.30M | - | - | - | - |
| Contract Development And Manufacturing | - | $113.30M | $450.50M | $80.00M | - |
| Contract Development And Manufacturing, Leases | - | - | $108.00M | - | - |
| Contracted Operating Leases | - | - | - | $165.30M | - |
Emergent BioSolutions's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (61.30%), Commercial Product (32.27%), Service (4.72%), and Contracts and Grants (1.71%).
Quarterly Revenue by Product
| Product/Service | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Sep 20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $249.10M | $249.80M | $302.20M | $143.40M | $305.70M | - | - | - | - | - | - | - |
| Service | $59.60M | $13.20M | - | - | $17.70M | - | - | - | - | - | - | - |
| Contracts and Grants | $6.70M | $6.50M | $6.60M | $6.50M | $7.10M | $17.40M | $7.30M | $9.60M | - | - | - | - |
| Contract Development And Manufacturing | - | $14.20M | $29.10M | $15.20M | $17.90M | - | - | - | - | - | - | - |
| Contract Development And Manufacturing, Leases | - | - | - | - | - | $200.00K | $400.00K | $104.20M | $114.60M | - | - | - |
| Contracted Operating Leases | - | - | - | - | - | - | - | - | - | $129.70M | $146.60M | $177.70M |
Emergent BioSolutions's latest quarterly revenue breakdown by segment (product or service), as of Dec 23: Product (78.98%), Service (18.90%), and Contracts and Grants (2.12%).
Emergent BioSolutions Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Services Segment | $78.50M | - | - | - | - |
| CANADA | - | $148.60M | - | - | - |
| UNITED STATES | - | $889.50M | $897.80M | $626.00M | $568.80M |
| Other Geographical Area | - | $82.80M | - | - | - |
| Non-US | - | - | $894.90M | $363.80M | $334.70M |
Emergent BioSolutions's latest annual revenue breakdown by geography, as of Dec 23: Services Segment (100.00%).
Quarterly Revenue by Country
| Country | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Services Segment | $20.00M | $14.20M | $29.10M | $15.20M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| UNITED STATES | - | - | - | - | $602.80M | $49.80M | $124.40M | $112.50M | $502.60M | $60.20M | $66.30M | $56.40M | $235.50M | $102.40M | $224.20M | $63.90M | $230.70M | $170.20M | $94.60M | $73.30M |
| Non-US | - | - | - | - | - | $190.20M | $118.30M | $195.00M | $220.60M | $268.80M | $114.90M | $81.50M | $105.40M | $99.80M | $74.30M | $84.30M | $80.10M | $86.00M | $88.90M | $79.70M |
Emergent BioSolutions's latest quarterly revenue breakdown by geography, as of Dec 23: Services Segment (100.00%).
Emergent BioSolutions Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BHC | Bausch Health Companies | $8.76B | $2.40B |
| ZTS | Zoetis | $8.54B | $2.36B |
| NBIX | Neurocrine Biosciences | $1.89B | $622.10M |
| ALKS | Alkermes | $1.66B | $378.14M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| EBS | Emergent BioSolutions | $1.05B | $254.70M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| DCPH | Deciphera Pharmaceuticals | $163.36M | $45.00M |
| LFCR | Lifecore Biomedical | $128.26M | $24.70M |
| CPIX | Cumberland Pharmaceuticals | $39.55M | $9.85M |
| DRRX | DURECT | $8.55M | $1.83M |
| AKAN | Akanda | $2.16M | $762.61K |
| PETQ | PetIQ | $1.10M | $328.94M |
EBS Revenue FAQ
What is Emergent BioSolutions’s yearly revenue?
Emergent BioSolutions's yearly revenue for 2023 was $1.05B, representing a decrease of -6.39% compared to 2022. The company's yearly revenue for 2022 was $1.12B, representing a decrease of -37.47% compared to 2021. EBS's yearly revenue for 2021 was $1.79B, representing an increase of 15.26% compared to 2020.
What is Emergent BioSolutions’s quarterly revenue?
Emergent BioSolutions's quarterly revenue for Q2 2024 was $254.7M, a -7.92% decrease from the previous quarter (Q4 2023), and a 54.27% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $276.6M, a 2.26% increase from the previous quarter (Q3 2023), and a -16.36% decrease year-over-year (Q4 2022). EBS's quarterly revenue for Q3 2023 was $270.5M, a -19.95% decrease from the previous quarter (Q2 2023), and a 12.71% increase year-over-year (Q3 2022).
What is Emergent BioSolutions’s revenue growth rate?
Emergent BioSolutions's revenue growth rate for the last 3 years (2021-2023) was -41.47%, and for the last 5 years (2019-2023) was -5.13%.
What are Emergent BioSolutions’s revenue streams?
Emergent BioSolutions's revenue streams in c 23 are Product, Contracts and Grants, Service, and Commercial Product. Product generated $944.5M in revenue, accounting 61.30% of the company's total revenue, down -2.25% year-over-year. Contracts and Grants generated $26.3M in revenue, accounting 1.71% of the company's total revenue, down -36.47% year-over-year. Service generated $72.8M in revenue, accounting 4.72% of the company's total revenue Commercial Product generated $497.3M in revenue, accounting 32.27% of the company's total revenue
What is Emergent BioSolutions’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Emergent BioSolutions was Product. This segment made a revenue of $944.5M, representing 61.30% of the company's total revenue.